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Genetic loci associated with an 
earlier age at onset in multiplex 
schizophrenia
Annemarie L. Woolston  1, Po-Chang Hsiao2, Po-Hsiu Kuo1,2,3, Shi-Heng Wang1,4, Yin-Ju 
Lien5, Chih-Min Liu6,7, Hai-Gwo Hwu  1,6, Tzu-Pin Lu1,8, Eric Y. Chuang8,9, Li-Ching Chang10, 
Chien-Hsiun Chen10, Jer-Yuarn Wu10, Ming T. Tsuang11,12,13 & Wei J. Chen  1,2,6,7
An earlier age at onset (AAO) has been associated with greater genetic loadings in schizophrenia. This 
study aimed to identify modifier loci associated with an earlier AAO of schizophrenia. A genome-wide 
association analysis (GWAS) was conducted in 94 schizophrenia probands with the earliest AAO and 
91 with the latest AAO. Candidate single nucleotide polymorphisms (SNPs) were then genotyped in 
the co-affected siblings and unrelated probands. Multi-SNP genetic risk scores (GRS) composed of 
the candidate loci were used to distinguish patients with an early or late AAO. The 14-SNP GRS could 
distinguish the co-affected siblings (n = 90) of the earliest probands from those (n = 91) of the latest 
probands. When 132 patients with an earlier AAO and 158 patients with a later AAO were included, 
a significant trend in the 14-SNP GRS was detected among those unrelated probands from 4 family 
groups with the earliest, earlier, later, and latest AAO. The overall effect of the 14 SNPs on an AAO in 
schizophrenia was verified using co-affected siblings of the GWAS probands and trend effect across 
unrelated patients. Preliminary network analysis of these loci revealed the involvement of PARK2, a 
gene intensively reported in Parkinson’s disease and schizophrenia research.
Schizophrenia has long been described as a complex disorder and its aetiology remains elusive1–3. Family and 
twin studies have indicated that genetic factors contributed substantially to schizophrenia, with an estimated 
heritability of approximately 80%4. When hundreds of microsatellite markers were examined in genome-wide 
linkage studies (GWLS) to look for genetic variants that co-segregated with the illness within families, suggestive 
evidence for a dozen of linkage regions was found5. With the advent of genome-wide association studies (GWAS), 
in which hundreds of thousands of single nucleotide polymorphisms (SNPs) were examined, approximately 100 
markers conferring small increments in risk have been found in schizophrenia6, 7.
Nevertheless, the combined variance explained by the SNPs reaching genome-wide significance remained 
low6. Alternatively, an application of GWAS data, the polygenic risk score (PRS), has been discovered6. The 
PRS, consisting of SNPs with P-values less than certain thresholds in GWAS, has been demonstrated to provide 
clues to functional analysis6, 8. Examination of the PRS derived from the results of large-scale GWAS6, 7 has been 
used to predict individuals with first-episode psychosis from controls9 and those predisposed to schizophrenia 
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in adolescence10. The associations between the PRS and some clinical dimensions of schizophrenia11 and 
first-episode psychosis12 have also been reported.
In search of the genetic factors contributing to schizophrenia, another class of genes involved in the clinical 
manifestations of the illness, i.e., modifier genes, also needs to be considered13. Modifier loci associated with clin-
ical features, such as the age at onset (AAO)14, 15 and positive and negative symptoms16 but not with schizophrenia 
susceptibility per se, have been identified using GWAS. Furthermore, our previous ordered subset linkage analysis 
identified a prominent linkage peak in a subset of schizophrenia patients characterized by earlier AAO17.
In this study, we aimed to identify genetic loci associated with earlier AAO of schizophrenia in multiplex 
families from a single ethnicity. We performed a case-only GWAS for AAO of schizophrenia in a multiplex family 
sample of Han Chinese in Taiwan. Individual SNPs above certain significance thresholds were further tested in 
two subsamples, including co-affected siblings and other unrelated patients from the same recruitment scheme. 
Then, a multi-SNP genetic risk score (GRS) was applied to estimate an overall effect of the candidate genetic 
loci. The influence of the AAO-modifying genetic loci on the susceptibility of schizophrenia was also evaluated 
to clarify the potential effect using additional population-based case-control and family-based association tests. 
Finally, candidate SNPs were subjected to gene network analysis to explore their possible functions associated 
with the AAO of schizophrenia.
Materials and Methods
Participants. The multiplex family samples used in this study were selected from the Taiwan Schizophrenia 
Linkage Study (TSLS). First-degree relatives from Han Chinese families with more than two children affected by 
schizophrenia were recruited across Taiwan. Detailed methods of the fieldwork have been described elsewhere18. 
Briefly, interviews at recruitment were performed using the Diagnostic Interview for Genetic Studies (DIGS)19, 
accompanied with the Family Diagnostic Interview for Genetic Studies (FIGS)20. Research assistants carried out 
a Chinese version of the DIGS, following standard training as described by Chen and colleagues21. The diagnosis 
of schizophrenia was made independently by at least two research psychiatrists based on the criteria of the fourth 
edition of the Diagnostic and Statistical Manual (DSM-IV), joined with the record of DIGS, FIGS, interviewer 
notes, and hospital anamnesis. Information regarding an AAO of the first psychotic episode was extracted from 
the psychosis section of DIGS, or from the medical history where necessary. Whole blood samples were collected 
and sent to the National Institute of Mental Health (NIMH) Repository and Genomics Resource (RGR) to be 
transformed into lymphoblastoid cell lines and stored. DNA samples were extracted from the cell lines and then 
transported to Taiwan.
The study design and selection of family samples are illustrated in Supplementary Figure S1. Among the 607 
families recruited by the TSLS18, 2242 individuals from 557 multiplex families, including 1207 affected (1150 sib-
lings, 57 parents) and 1035 unaffected (271 siblings and 764 parents) individuals, were successfully genotyped in 
a genome-wide linkage analysis22. Previous GWLS of these multiplex families indicated that a subset of families 
with early AAO led to a significant linkage signal17. Hence, we postulated that a GWAS screening based on a sub-
sample with extreme contrast in AAO might maximize the power to identify candidate modifier genetic variants. 
Nevertheless, the chosen variants could then be genotyped in the remaining samples for the confirmation of the 
association with AAO. First, the 557 families were ranked according to the average AAO of the siblings affected by 
schizophrenia from each family. Second, a power evaluation of a two-group design (patients with extremely early 
AAO vs. patients with extremely late AAO) with 80 patients in each group reached 0.7–0.9 using Genetic Power 
Calculator23 under the following conditions: the minor allele frequencies of the SNPs are 0.2–0.45; the genotype 
relative risk for heterozygote and homozygote are 1.9–2.0 and 2.0–2.2, respectively; and the prevalence of early 
AAO among patients on average is 0.3–0.5, according to our empirical data. The final sample size increased from 
80 to 95 per group since the microarray chips used in this study could hold 190 samples. Hence, the 95 families 
with the earliest average AAO and the 95 families with the latest average AAO were identified as the subsample 
with an extreme contrast in the AAO. One proband with an AAO conforming to the contrast from each family 
(i.e., earlier AAO in the extremely early subgroup and later AAO in the extremely late subgroup) was selected for 
GWAS genotyping. After sample quality control (discussed later), 185 probands (94 of the earliest AAO subgroup 
and 91 of the latest AAO subgroup) remained. SNPs with the strongest association signals (P-value < 10−4) in the 
association tests were identified as a set of candidate SNPs. Third, the co-affected siblings (n = 181), whose DNA 
material were available, from the initial 185 families were then genotyped for the consideration that their genetic 
background was similar to the initial probands.
Another two subgroups of schizophrenia patients were selected from the remaining families with less contrast 
in average AAO. However, the number of patients that could be genotyped was determined by the slots available 
for candidate loci genotyping after the co-affected sibling and parents of the initial 185 probands, i.e., at most 300 
samples. Using similar principles in selecting one patient from each family as before, 132 patients from families 
of earlier AAO and 158 patients from families of later AAO were then genotyped for the candidate SNPs. Along 
with the 185 initial probands with extremely early AAO (n = 94) and extremely late AAO (n = 91), those unre-
lated schizophrenia patients could be divided into four subgroups (the earliest, earlier, later, and latest AAO) and 
exhibited an increasing trend of average AAO (Supplementary Figure S2). This four-group contrast provided an 
opportunity to examine a gradient effect of the candidate loci on AAO. The remaining 77 families with modest 
contrast in the average AAO were not included for the genotyping of candidate loci in consideration of the effi-
ciency of the trend analyses.
To evaluate whether the candidate SNPs associated with AAO were also involved in susceptibility for schiz-
ophrenia, two strategies of association analysis were adopted. The first strategy was to genotype the parents 
(n = 288) from the initial 185 probands and then to pool them with the affected siblings to undergo family-based 
association test for schizophrenia. The second strategy was to conduct a case-control association analysis. 
Community controls free of major mental disorders were selected from the Han Chinese Cell and Genome Bank 
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in Taiwan (HCCGB)24 using a frequency matching in age and gender distribution with a 5 to 1 ratio of controls 
versus cases25. A total of 925 community controls were selected to match the 185 probands with genome-wide 
SNP data (Supplementary Figure S1).
SNP genotyping and quality controls. The genome-wide SNP genotyping was performed on 190 schiz-
ophrenia probands of extreme contrast in AAO using the Axiom Genome-wide CHB 1 Array Plate (Affymetrix, 
Santa Clara, CA, USA). A total of 642,832 SNP genotypes were examined. Quality control of the samples and 
markers was performed according to the standard procedure for GWAS26, and was mainly performed using 
PLINK 1.0727. Briefly, SNP data from each proband were checked for gender inconsistency and sample genotyp-
ing call rate (>98%).
All genetic markers were checked for marker genotyping call rate (>98%), minor allele frequency (>0.05), 
and Hardy-Weinberg equilibrium (HWE) with a P-value of >0.001. For population stratification, or check for 
the homogeneity of the sample, we followed the procedures provided by PLINK. The whole-genome identical 
by state (IBS) distances were firstly calculated between all individuals. Four multidimensional scaling (MDS) 
components of each individual were then estimated using the Hamming distance. A MDS component with a 
significant difference in the comparison would be adjusted as a covariate in the GWAS analyses. Relatedness 
between probands was estimated based on pairwise kinship using the KING software28. Batch effects were also 
checked and adjusted. Finally, 185 probands with schizophrenia remained after the quality control measures, with 
5 patients being deleted due to low call rates (n = 2), a high kinship with another proband (n = 1), or population 
stratification suggesting different ancestry (n = 2). A total of 564,836 SNPs remained after the quality control. The 
overall genotyping error was 0.42%. Afterwards, the genomic inflation factor was very small (λ = 1.0013).
Genotyping for the candidate SNPs in available co-affected siblings and parents and an independent set of 
schizophrenia probands with less contrast in AAO was carried out using the Illumina GoldenGate Genotyping 
Assay, which allows for customising probes of the SNPs of interest. The SNP genotyping of the community con-
trols was performed by the biobank using the same microarray chip (Affymetrix Axiom Genome-wide CHB 
1 Array Plate) as used for the schizophrenia probands. Only the data of the candidate SNPs in the community 
controls are presented in this study.
Data analyses. A two-tailed Fisher’s exact test for dichotomous variables and a two-tailed t-test for con-
tinuous variables were used for group comparisons. Multiple logistic regression with adjustment for one of the 
four MDS components was used for association analysis for individual SNPs between GWAS probands from 
families with extreme contrast in AAO. We did not include covariates such as age and gender in the regression 
models to increase the power when searching for new genetic loci in diseases with low prevalence like schizo-
phrenia29. Because age and AAO of the patients in the TSLS sample (n = 1,285) were highly correlated, with a 
Pearson’s correlation coefficient (r) = 0.52, we did not adjust for age in subsequent association analyses in the 
data sets of individual genotyping. Furthermore, we did not adjust for gender in these analyses since only auto-
somal SNPs were included in our GWAS analysis. Multiple comparisons of the association tests on the candidate 
SNPs were adjusted using Bonferroni correction. A P-value lower than 7.2 × 10−8 was considered the threshold 
of genome-wide significance30, while a less stringent threshold of P-value < 10−4 was used to filter SNPs with the 
strongest association. Owing to these considerations, simple logistic regression analyses were used for the analysis 
of the co-affected siblings of the initial GWAS probands. Ordinal logistic regression was used to examine whether 
there was a linear trend in the allele frequency of a candidate SNP across schizophrenia probands from the earli-
est, earlier, later, and latest AAO family subgroups. Nevertheless, to exclude potential confounding by gender we 
also performed alternative statistic models with adjustment for gender in the analysis of co-affected siblings and 
the 4 groups of unrelated probands.
Multi-SNP GRS was constructed by sum of logarithm of odds ratio (logOR) multiplied by genotypes (coded 
as 0, 1 and 2) of the candidate SNPs with 0 for the homozygosity of major allele, 1 for the heterozygosity, and 2 for 
homozygosity of minor allele. The GRS were estimated using the logOR from the GWAS analysis of 185 probands 
and presented as the means ± standard error. Comparisons between the earliest and the latest AAO family sub-
groups using non-parametric Mann-Whitney U-test were performed separately among the probands and their 
co-affected siblings. The trend test for the GRS between the four AAO family subgroups was carried out using 
linear regression.
The influence of the AAO-associated SNPs on the susceptibility to schizophrenia was evaluated using 
both family-based and population-based designs. First, for those families with SNP genotyping information, 
family-based association analyses were performed using software family-based association test (FBAT) version 
2.0.331, with affected status as outcome and the additive model for genotypes. Second, the schizophrenia probands 
with GWAS genotyping and their age- and gender-matched community controls were subjected to association 
analysis using multiple logistic regression with adjustment for age and gender to avoid selection bias.
The possible function of a SNP was predicted by the GoldenPath as described in the F-SNP database (http://
compbio.cs.queensu.ca/F-SNP). Then, those candidate SNPs with gene annotation were subjected to network 
analyses using the Ingenuity Pathway Analysis (IPA; http://www.qiagen.com/ingenuity). The significance level of 
the gene network analysis was determined using -log10(P-value) and noted as the p-score.
Ethics statement. This study has been approved by the National Taiwan University Hospital Research Ethics 
Committee (NTUH-REC, No.: 201003106 R and 201411086RINC) for the analyses including all relevant details. 
The use of personal information and DNA samples for genotyping experiments were performed in accordance 
with the NTUH-REC guidelines and regulations. The sample collections of families with schizophrenia and 
normal controls were approved by the National Taiwan University Hospital’s Internal Review Board of Human 
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Studies and the Internal Review Board of the Institute of Biomedical Sciences, Academia Sinica as described in 
the articles of the filed work18, 24.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
For the 185 families with extreme contrast in AAO, the difference in AAO for both the probands and their 
co-affected sibling subsamples were significant between families with the earliest AAO and those with the latest 
AAO (Table 1). Further, the difference in AAO for an independent set of probands (n = 290) from other families 
with less contrast in AAO was also significant. For those families with affected parents, the average AAO of the 
affected parents from families with the earliest AAO was younger than those with the latest AAO, and parental 
AAOs were later than their affected children, regardless of family subgroups. The distribution of gender did not 
differ among groups. However, the average age of the members from families with an early AAO was statistically 
younger than that of the families with an early AAO.
Genome-wide association study. The Manhattan plot of the initial GWAS analysis among schizophre-
nia probands from families with extreme contrast in AAO is displayed Fig. 1, with none reaching genome-wide 
significance. Nevertheless, 17 SNPs reached a suggestive threshold (P-values < 10−4). Table 2 displays the names, 
locations, minor allele frequencies (MAF), odds ratios (OR), and P-values of the association on 17 candidate 
SNPs, which are located on chromosome 1, 4, 6, 7, 18, 19, and 21. All the empirical P-values of the 17 SNPs 
remained less than 10−4 after 108 times of permutation. Among these SNPs, 9 were mapped to the introns of 7 
genes, whereas the remaining SNPs were in intergenic regions. Three intronic SNPs (rs3016537, rs7755434, and 
rs60117510) were mapped to the same intron in PARK2, spaced less than 300 base pairs apart with high linkage 
disequilibrium (LD); therefore, only one SNP (rs60117510) with the smallest P-value was included in the subse-
quent analyses.
Candidate SNPs in additional subsamples. These 15 SNPs were then genotyped in two additional 
samples: 1) the 181 co-affected siblings of the initial probands with extreme contrast in AAO and 2) the 290 
unrelated probands from the remaining families with less contrast in average AAO (Table 2), with rs6426994 
being excluded from analysis due to its low call rate. Among the co-affected sibling subsample from the fam-
ilies with extreme contrast in AAO, 5 SNPs exhibited significant associations (P-values < 0.05). Only the 
SNP on PARK2 (rs60117510 with P < 0.001) remained significant after adjustment for multiple comparisons 
(P-value < 0.0036 = 0.05/14).
Regarding the 290 unrelated probands from the remaining families with less contrast in the AAO, none of 
the 14 SNPs reached statistical significance. Nevertheless, when the patients from the initial 185 probands with 
extreme contrast in the AAO and the 290 probands from the remaining families with less contrast in the AAO 
were examined as unrelated patients from four family subgroups (earliest, earlier, later, and latest AAO), all the 14 
SNP genotypes showed a significant trend for the AAO (Table 2). The results of statistical models with adjustment 
for gender among the co-affected siblings and the unrelated gradient AAO groups remain similar (Supplementary 
Table S2).
Multi-SNP genetic risk scores. To obtain a multi-SNP GRS composed of the 14 candidate SNPs, the 185 
probands with GWAS data were used as the learning set, in which the logOR were used as the weighting system. 
The probands with earliest AAO had greater 14-SNP GRS than those with latest AAO (left panel in Fig. 2). Then, 
the weights of the 14 SNPs were carried over to calculate the corresponding GRS among the 181 co-affected 
Extreme contrast in the AAO Less contrast in the AAO
All Earliest AAO Latest AAO P-value All Earlier AAO Later AAO P-value
Probands n = 185 n = 94 n = 91 n = 290 n = 132 n = 158
Male, n (%) 117 (63%) 53 (56%) 64 (70%) 0.06 192 (66%) 87 (66%) 105 (66%) 1
Age, mean (SD) 35.0 (8.4) 30.2 (7.5) 39.9 (6.0) <0.0001 35.1 (7.4) 32.2 (7.1) 37.6 (6.6) <0.0001
AAO, mean (SD) 23.7 (9.2) 15.1 (1.6) 32.6 (3.7) <0.0001 23.1 (5.8) 18.6 (2.4) 26.8 (5.0) <0.0001
Co-affected siblings n = 181 n = 90 n = 91
Male, n (%) 111 (61%) 57 (63%) 54 (59%) 0.64
Age, mean (SD) 34.8 (8.6) 30.6 (7.5) 38.9 (7.6) <0.0001
AAO, mean (SD) 21.4 (4.8) 19.6 (3.4) 23.1 (5.3) <0.0001
Parents n = 288 n = 156 n = 132
Male, n (%) 127 (44%) 73 (47%) 54 (41%) 0.34
Age, mean (SD) 63.1 (9.2) 59.3 (8.7) 67.7 (7.5) <0.0001
Affected, n (%) 21 (7.3%) 13 (8.3%) 8 (6.1%) 0.50
AAO, mean (SD) 32.9 (11.0) 28.8 (8.7) 43.0 (14.8) 0.02
Table 1. Comparison of gender, age, and age at onset distribution of the family samples with extreme and less 
contrast in the age at onset. AAO: age at onset.
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siblings of the GWAS probands, and the comparisons of the GRS between the two types of families remained 
significant, although the magnitude of contrast decreased (left panel in Fig. 2). Furthermore, the 14-SNP GRS 
for the 290 unrelated probands from the remaining families with less contrast in the AAO were calculated and 
used in the analysis of the unrelated patients from four family subgroups (earliest, earlier, later, and latest AAO), a 
significant trend of the GRS was observed (right panel in Fig. 2). All comparisons of the 14-SNP GRS maintained 
the statistical significance (P < 0.0001) with adjustment for gender (data not shown).
AAO-associated SNPs and susceptibility. The relationship between the 14 AAO-associated SNPs and 
susceptibility to schizophrenia was analysed using two approaches (Table S1). First, the association between 
the 14 candidate SNPs and affliction with schizophrenia was examined using an additive model of the FBAT 
within the 185 multiplex families. The results showed that only 1 SNP (rs571002) had a weak association signal 
(P = 0.049). Second, by incorporating 925 age- and gender-matched community controls with the initial 185 
schizophrenia probands, the conventional case-control association tests indicated that none of the 14 SNPs had 
different allele frequencies between the cases and the controls.
Network analysis. Out of the 14 candidate SNPs identified associated with an early AAO, 7 were located 
within introns. These 7 SNPs were then subjected to the network analysis. The results revealed 5 significant gene 
networks with p-score >2, including a larger network centering on PARK2 and 4 small networks consisting of 
N4BP2, and KCNIP4, ADGRL2, and NCOA7, respectively (Supplementary Figure S1). These 5 networks could 
be merged into a complicated scheme that may be involved in known diseases or biological functions, such as 
nervous system development, molecular transport, hereditary disorder, or cell-to-cell signaling and interaction. 
Detailed information on these networks is shown in Supplementary Table S3.
Discussion
In this study, we identified 14 genetic loci represented by SNPs that were associated with an earlier AAO in a series 
of patients affected by schizophrenia from multiplex families with Han Chinese ancestry in Taiwan. Initially, 14 
SNPs with the most significant association signals (P-value < 10−4) were obtained in a GWAS analysis for AAO 
among schizophrenia probands from two subgroups of families with extreme differences in the AAO (earliest 
AAO versus latest AAO). The association of the 14 SNPs were further evaluated in the co-affected siblings of 
the GWAS probands as well as in the probands from the families with less contrast in the AAO. When unrelated 
probands from four family subgroups (earliest, earlier, later, and latest AAO) were examined, all the 14 SNPs 
showed a significant trend for the AAO. A multi-SNP GRS consisting of the 14 candidate SNPs was able to dis-
tinguish probands with the earliest AAO from those with the latest AAO. Then, the discriminative validity of the 
Figure 1. Manhattan plot of a genome-wide association study for the age at onset of schizophrenia performed 
in 94 probands from multiplex families with the earliest AAO and those with 91 the latest AAO. The x-axis is 
the chromosomal position, and the y-axis is the significance of the association represented by -log10(P-value) 
derived from multiple logistic regression analyses. The horizontal blue line shows the significance threshold at 
-log10(P-value) >4 for candidate SNPs.
www.nature.com/scientificreports/
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GRS was further confirmed in the co-affected siblings of the GWAS probands as well as the unrelated probands 
from the four family subgroups characterized by an average AAO.
Some issues on our study design should be noted. First, this study primarily aimed to identify modifier loci 
associated with an earlier AAO of schizophrenia using a case-only design rather than susceptibility loci of schiz-
ophrenia using a case-control design. Second, we selected patients from families with contrast in AAO to con-
duct a dichotic comparison for association analyses instead of using patient onset age as a continuous outcome. 
Nevertheless, the linear trends detected for individual SNPs among the four ordinary AAO subgroups (earliest, 
earlier, later, and latest AAO) did indicate certain dosage effects. Third, limiting our patients to a single ethnicity 
may help decrease potential confounding effects from population admixture. Finally, adopting the PRS typically 
constructed from thousands of SNPs, we estimated a multi-SNP GRS composed of the 14 SNPs and confirmed its 
Chr SNP Position Gene
GWAS probands of extreme contrast in the AAO 
(n = 185)
Co-affected siblings of extreme 
contrast in the AAO (n = 181)
Trend of the AAO 
among 4 groups 
of probands§ 
(n = 475)
ALm MAFE MAFL ORa P-value
Empirical 
P-value MAFE MAFL ORa P-value ORb P-value
1 rs12118952 81,445,881 ADGRL2 A 0.25 0.46 0.38 3.8 × 10−5 1.6 × 10−5 0.30 0.40 0.66 0.06 0.66 8.9 × 10−4
1 rs6426994 166,361,616 FMO7P G 0.30 0.49 0.39 9.6 × 10−5 5.5 × 10−5 — — — — — —
1 rs609832 211,552,050 RD3/SLC30A1 G 0.18 0.04 6.32 3.6 × 10−5 5.3 × 10−6 0.14 0.07 2.44 0.02 1.95 8.9 × 10−4
1 rs2378013 218,778,121 TGFB2 A 0.41 0.20 2.68 7.5 × 10−5 3.6 × 10−5 0.33 0.26 1.44 0.13 1.62 5.9 × 10−4
4 rs923673 20,789,574 KCNIP4 C 0.30 0.12 4.08 1.3 × 10−5 3.2 × 10−6 0.25 0.17 1.69 0.06 1.69 3.4 × 10−4
4 rs11930588 40,179,089 N4BP2 T 0.49 0.30 3.02 5.1 × 10−5 1.6 × 10−5 0.43 0.36 1.41 0.14 1.46 1.7 × 10−4
6 rs2506754 103,548,429 R3HDM2P2 A 0.30 0.12 3.94 1.2 × 10−5 1.9 × 10−6 0.22 0.18 1.37 0.25 1.88 2.6 × 10−3
6 rs12210422 103,595,851 R3HDM2P2 G 0.35 0.15 3.01 8.9 × 10−5 3.8 × 10−5 0.30 0.25 1.31 0.26 1.64 5.5 × 10−6
6 rs6900852 125,901,926 NCOA7 G 0.37 0.43 0.39 9.8 × 10−5 5.2 × 10−5 0.42 0.49 0.73 0.14 0.62 1.0 × 10−4
6 rs3016537 161,816,611 PARK2 C 0.13 0.30 0.27 4.1 × 10−5 1.6 × 10−5 — — — — — —
6 rs7755434 161,816,624 PARK2 A 0.12 0.29 0.26 2.7 × 10−5 9.6 × 10−6 — — — — — —
6 rs60117510 161,816,881 PARK2 C 0.12 0.29 0.25 2.2 × 10−5 9.1 × 10−6 0.12 0.26 0.40 0.001 0.64 2.5 × 10−3
7 rs6964070 4,463,521 SDK1/FOXK1 G 0.53 0.35 2.63 9.3 × 10−5 4.5 × 10−5 0.49 0.36 1.73 0.01 1.51 1.1 × 10−3
7 rs1589988 16,227,085 ISPD A 0.18 0.34 0.34 7.6 × 10−5 2.9 × 10−5 0.20 0.31 0.55 0.02 0.62 4.0 × 10−4
18 rs571002 13,090,667 CEP192 T 0.22 0.42 0.33 7.7 × 10−5 3.8 × 10−5 0.29 0.36 0.73 0.17 0.61 1.5 × 10−4
19 rs371164 6,489,802 DENND1C/TUBB4A G 0.53 0.40 2.52 6.3 × 10−5 2.9 × 10−5 0.49 0.34 1.98 0.004 1.53 4.2 × 10−4
21 rs2830964 27,474,617 RPL10P1/NCSTNP1 C 0.22 0.39 0.34 8.4 × 10−5 3.8 × 10−5 0.27 0.32 0.72 0.19 0.65 8.0 × 10−4
Table 2. The SNPs with suggestive signal associated with age at onset of schizophrenia between different 
comparisons Chr: chromosome; bold: SNP within the gene; italics: SNP near the gene; ALm: minor allele; AAO: 
age at onset; MAFE/MAFL: minor allele frequency in patients from families with earliest/latest AAO; ORa: 
odds ratio from association test using logistic regression; ORb: odds ratio from trend test using ordinal logistic 
regression. Empirical P presented the P-values obtained after up to 108 times of permutation of the multiple 
logistic model. §The trend effect of each SNP was tested using ordinal logistic regression among 4 groups of 
probands from families with earliest, earlier, later, and latest AAO of schizophrenia.
Figure 2. Multi-SNP genetic risk scores composed of the 14 SNPs associated with age at onset of schizophrenia. 
The left panel shows the difference of the 14-SNP genetic risk scores among both probands (94 with earliest 
and 91 with latest AAO) and co-affected siblings (90 with earliest and 91 with latest AAO) between two family 
groups, with a P-value < 0.0001 using the non-parametric Mann-Whitney U-test. The right panel shows a 
significant trend of the 14-SNP genetic risk scores among the probands from 4 family groups with a gradient 
AAO (earliest, earlier, later, and latest AAO), with a P-value < 0.0001 using the trend test using linear regression.
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combined effect on the modification of the AAO across our family samples. The converging results from multiple 
lines of evidence provide robustness to our findings.
An important feature of this study is that we used patients from multiplex families with co-affected sib-pairs 
to search for modifier genetic loci associated with an early AAO in schizophrenia. Both an earlier AAO and a pos-
itive family history imply greater genetic contributions in these patients with schizophrenia14, 15. Given the same 
number of individuals that could be genotyped using GWAS chip under the constraints of resources, comparing 
two groups of multiplex schizophrenia patients with extreme contrast in AAO might have better power in detect-
ing the associated genetic variants. The remaining co-affected sibling in each family become a genetically similar 
group for confirming the associations derived from the initial earliest vs. the latest onset probands. Using patients 
with relatively homogeneity in genetic loadings might also account for our success in confirming the initial hits 
from the GWAS results, which is typically more difficult in regular case-control studies due to heterogeneous back-
ground6, 7. In addition, we chose a threshold less stringent than the genome-wide significance level to select sug-
gestive loci for further investigation, which has been adopted in many post-GWAS studies of schizophrenia15, 32. 
Nevertheless, the associations of these suggestive loci with AAO among the other co-affected siblings as well as 
multiplex patients from other families with less contrast in AAO lend consistent support to the initial selection.
Further, we applied a series of samples to confirm the association of 14 candidate loci with AAO in schizo-
phrenia. The 2 groups of unrelated probands with less contrast of AAO was pooled into the initial 185 probands 
to conduct a gradient characteristic, considering the use of patients from multiplex families to reduce heteroge-
neity. Although not all individual SNPs conformed to the prediction in the samples consisting of patients with 
less contrast in the AAO, all of them exhibited a significant linear trend when pooling all 4 groups of unrelated 
probands together. With the gradient AAO among the 4 family groups, we substantiated that the AAO-modifying 
loci found in a dichotic design had implied a trend effect across the whole multiplex family sample. Nevertheless, 
alternative statistic models with adjustment for gender did not show evident changes in the significance of the 
association in single SNP and multi-SNP GRS analyses.
Among the 14 genetic loci we identified as AAO-associated in schizophrenia, 7 are intronic and another 7 are 
intergenic. The 7 SNPs or their surrounding regions within genes have been reported to be related to neurological 
disorders, such as schizophrenia22, 33–37 and Parkinson’s disease38–40 in previous GWLS and GWAS. The network 
analysis of the 7 annotated genes revealed 5 networks, each with PARK2, N4BP2, KCNIP4, ADGRL2, or NCOA7 
as its focus gene, which may have joint influence on the initiation of schizophrenia.
Though preliminary in nature, there have been clues about possible involvement of these genes in neurological 
diseases. First, ADGRL2 at chromosome 1p31.1 had a nonparametric linkage Z score of 2.08 for marker D1S551 
related to schizophrenia in the GWLS conducted in the original TSLS families22, indicating a consistent signal in 
both linkage and association studies. Intriguingly, the same linkage signal on 1p31.1 was also reported in a GWLS 
for schizophrenia in an Indian sample of 124 affected sib-pair families33. Second, a few SNPs on KCNIP4 were 
suggestively associated with schizophrenia34, suicidal ideation in major depression41 and childhood ADHD42, 43 
in GWAS, implying a function underlying these neuropsychiatric illnesses. Third, N4BP2 at chromosome 4p14 
was reported in linkage studies of schizophrenia35 and Parkinson’s disease39. Fourth, NCOA7 was associated with 
Parkinson’s disease in GWAS40, and its expression was upregulated in the brain than in other human tissues44. Last 
but not least, mutations in PARK2 at 6q25.2-q27 have been intensively studied in Parkinson’s disease, especially 
those with early onset45. There is increasing evidence pointing to a potential overlapping pathogenesis between 
Parkinson’s disease and schizophrenia since they had opposite dopaminergic dysfunctions, similar psychotic 
symptoms46, and shared some gene networks47.
Furthermore, 2 of the intergenic loci (SNP rs609832 and rs2378013) were predicted to have transcriptional 
regulation function, although the targets remained unclear. Unlike non-synonymous variants in exons, intronic 
and intergenic loci may serve as markers reflecting nearby genetic variants with functional meaning in schizo-
phrenia48. Taken together, these genetic loci may have modifier functions for an earlier AAO in schizophrenia, 
although biological evidence is needed for further confirmation. The results of our GWAS for AAO in schizophre-
nia provide potential genetic markers and functional targets for future investigation.
While many GWAS for schizophrenia have been published, only two GWAS focusing on modifier loci respon-
sible for AAO of schizophrenia have been conducted14, 15. Using schizophrenia patients of European ancestry, 
these two studies did not separate patients into those with and without family history when they analysed GWAS 
for the AAO. Each study identified multiple genetic loci that were associated with a quantitative AAO with a 
nominal significance level of P-value < 10−6 but could not validate them in the replication samples. Nevertheless, 
the loci identified by these two studies and our study did not overlap. One explanation for the inconsistent results 
could be the ethnic heterogeneity among studies49. Another explanation could be the difference in the scale of 
AAO, i.e., our use of subgroups with extreme contrast in AAO versus the use of continuous AAO in the other 
two studies.
It is noteworthy that none of the 14 AAO-modifying genetic loci found in this study were reported in the 108 
genetic loci for schizophrenia susceptibility reported by an international collaborative effort7. This highlights a 
growing recognition that modifier genes may involve mechanisms in the pathogenesis of schizophrenia that are 
different from those of susceptibility genes13. The discovery of modifier genetic loci may also contribute to the 
phenomenon of missing heritability in the GWA results of schizophrenia50.
Some limitations should be noted in this study. First, the number of probands was small in the initial GWAS 
for the AAO of schizophrenia. Nevertheless, using multiplex patients of single ethnic group may help increase the 
homogeneity of our family sample. Second, an independent sample for replication would be required for further 
confirmation of our results. Of note, collecting multiplex families of sib-pairs co-affected with schizophrenia 
would be a substantial endeavour. Third, our network analysis was limited by both the restricted annotation of 
SNPs located within genes and the inability to incorporate the intergenic regions in the analysis. Finally, the func-
tions of the AAO-modifying loci warrant further investigation.
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In conclusion, this study identified 14 modifier loci that are associated with the AAO of schizophrenia, and 
a multi-SNP GRS composed of these 14 loci can distinguish patients with an early AAO from those with a late 
AAO. The use of co-affected siblings and unrelated patients with a gradient AAO for confirmation of the initial 
GWAS provided a novel strategy to overcome a drawback of the small sample. Future investigation of these 
AAO-modifying genetic loci may help further illuminate the pathogenesis of schizophrenia.
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